Search results
Showing 706 to 720 of 729 results for innovative
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.
Speaking with one language: How using a common data model might speed up decision making
The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.